# Citius Oncology, Inc.: financial statements, quarterly

CTOR · Nasdaq · CIK 1851484 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Sep 30

Pages: [Overview](/companies/ctor.md) · [Financials](/companies/ctor/financials.md) · [Filings](/companies/ctor/filings.md) · [Insiders](/companies/ctor/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ctor/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [3.9](/filings/0001213900-26-015877.md) | [1.7](/filings/0001213900-26-057841.md) | [1.5](/filings/0001213900-26-090184.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.8](/filings/0001213900-26-015877.md) | [0.3](/filings/0001213900-26-057841.md) | [0.5](/filings/0001213900-26-090184.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [3.2](/filings/0001213900-26-015877.md) | [1.3](/filings/0001213900-26-057841.md) | [1.0](/filings/0001213900-26-090184.md) |
| Research and development | $m | not reported | [1.1](/filings/0001213900-25-014320.md) | [1.3](/filings/0001213900-25-043359.md) | [1.1](/filings/0001213900-25-074992.md) | [1.3 d](/filings/0001213900-25-125331.md) | [1.3](/filings/0001213900-26-015877.md) | [3.1](/filings/0001213900-26-057841.md) | [0.9](/filings/0001213900-26-090184.md) | [1.1 d](/filings/0001213900-25-125331.md) | [1.0](/filings/0001213900-26-015877.md) | [1.1](/filings/0001213900-26-057841.md) | [0.2](/filings/0001213900-26-090184.md) |
| Operating income | $m | [(0.4)](/filings/0001493152-23-042170.md) | [(0.2) d](/filings/0001493152-24-014850.md) | [(0.3)](/filings/0001493152-24-020783.md) | [(4.6)](/filings/0001213900-25-074992.md) | [(6.7) d](/filings/0001213900-25-125331.md) | [(6.4)](/filings/0001213900-26-015877.md) | [(7.5)](/filings/0001213900-26-057841.md) | [(4.9)](/filings/0001213900-26-090184.md) | [(4.7) d](/filings/0001213900-25-125331.md) | [(5.3)](/filings/0001213900-26-015877.md) | [(28.6)](/filings/0001213900-26-057841.md) | [(8.7)](/filings/0001213900-26-090184.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.2](/filings/0001213900-26-090184.md) | [0.1 d](/filings/0001213900-25-125331.md) | [0.0](/filings/0001213900-26-015877.md) | [0.0](/filings/0001213900-26-057841.md) | [0.2](/filings/0001213900-26-090184.md) |
| Income tax | $m | not reported | [0.1](/filings/0001213900-25-014320.md) | [0.1](/filings/0001213900-25-043359.md) | [0.1](/filings/0001213900-25-074992.md) | [0.1 d](/filings/0001213900-25-125331.md) | [0.3](/filings/0001213900-26-015877.md) | [0.3](/filings/0001213900-26-057841.md) | [0.3](/filings/0001213900-26-090184.md) | [0.3 d](/filings/0001213900-25-125331.md) | [0.3](/filings/0001213900-26-015877.md) | [(0.2)](/filings/0001213900-26-057841.md) | [(0.1)](/filings/0001213900-26-090184.md) |
| Net income | $m | [0.2](/filings/0001493152-23-042170.md) | [(4.7)](/filings/0001213900-25-074992.md) | [(4.8)](/filings/0001213900-25-074992.md) | [(4.8)](/filings/0001213900-25-074992.md) | [(6.8) d](/filings/0001213900-25-125331.md) | [(6.7)](/filings/0001213900-26-090184.md) | [(7.7)](/filings/0001213900-26-090184.md) | [(5.4)](/filings/0001213900-26-090184.md) | [(5.0) d](/filings/0001213900-25-125331.md) | [(5.5)](/filings/0001213900-26-090184.md) | [(26.6)](/filings/0001213900-26-090184.md) | [(8.9)](/filings/0001213900-26-090184.md) |
| Diluted EPS | $ per share | [0.02](/filings/0001493152-23-042170.md) | [(0.07)](/filings/0001213900-25-014320.md) | [(0.07)](/filings/0001213900-25-043359.md) | [(0.07)](/filings/0001213900-25-074992.md) | not reported | [(0.09)](/filings/0001213900-26-015877.md) | [(0.11)](/filings/0001213900-26-057841.md) | [(0.08)](/filings/0001213900-26-090184.md) | not reported | [(0.06)](/filings/0001213900-26-015877.md) | [(0.27)](/filings/0001213900-26-057841.md) | [(0.08)](/filings/0001213900-26-090184.md) |
| Basic EPS | $ per share | [0.02](/filings/0001493152-23-042170.md) | [(0.07)](/filings/0001213900-25-014320.md) | [(0.07)](/filings/0001213900-25-043359.md) | [(0.07)](/filings/0001213900-25-074992.md) | not reported | [(0.09)](/filings/0001213900-26-015877.md) | [(0.11)](/filings/0001213900-26-057841.md) | [(0.08)](/filings/0001213900-26-090184.md) | not reported | [(0.06)](/filings/0001213900-26-015877.md) | [(0.27)](/filings/0001213900-26-057841.md) | [(0.08)](/filings/0001213900-26-090184.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating, us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.0](/filings/0001493152-23-042170.md) | [0.0](/filings/0001493152-24-030991.md) | [0.0](/filings/0001493152-24-020783.md) | [0.0](/filings/0001493152-24-030991.md) | [0.0](/filings/0001213900-25-043359.md) | [0.0](/filings/0001213900-25-014320.md) | [0.0](/filings/0001213900-25-043359.md) | [0.0](/filings/0001213900-25-074992.md) | [3.9](/filings/0001213900-26-090184.md) | [7.3](/filings/0001213900-26-015877.md) | [2.6](/filings/0001213900-26-057841.md) | [16.6](/filings/0001213900-26-090184.md) |
| Current assets | $m | [7.7](/filings/0001213900-24-113150.md) | [0.1](/filings/0001493152-24-030991.md) | [0.1](/filings/0001493152-24-020783.md) | [0.0](/filings/0001493152-24-030991.md) | [11.0](/filings/0001213900-25-125331.md) | [17.1](/filings/0001213900-25-014320.md) | [18.0](/filings/0001213900-25-043359.md) | [18.3](/filings/0001213900-25-074992.md) | [27.5](/filings/0001213900-26-090184.md) | [37.1](/filings/0001213900-26-015877.md) | [29.4](/filings/0001213900-26-057841.md) | [42.7](/filings/0001213900-26-090184.md) |
| Total assets | $m | [47.7](/filings/0001213900-24-113150.md) | [72.6](/filings/0001493152-24-030991.md) | [48.7](/filings/0001493152-24-020783.md) | [49.2](/filings/0001493152-24-030991.md) | [84.4](/filings/0001213900-25-125331.md) | [90.5](/filings/0001213900-25-014320.md) | [91.4](/filings/0001213900-25-043359.md) | [91.7](/filings/0001213900-25-074992.md) | [101](/filings/0001213900-26-090184.md) | [110](/filings/0001213900-26-015877.md) | [101](/filings/0001213900-26-057841.md) | [112](/filings/0001213900-26-090184.md) |
| Current liabilities | $m | [21.0](/filings/0001213900-24-113150.md) | [2.0](/filings/0001493152-24-030991.md) | [2.8](/filings/0001493152-24-020783.md) | [3.1](/filings/0001493152-24-030991.md) | [32.7](/filings/0001213900-25-125331.md) | [43.4](/filings/0001213900-25-014320.md) | [49.7](/filings/0001213900-25-043359.md) | [53.0](/filings/0001213900-25-074992.md) | [49.5](/filings/0001213900-26-090184.md) | [44.7](/filings/0001213900-26-015877.md) | [58.8](/filings/0001213900-26-057841.md) | [58.8](/filings/0001213900-26-090184.md) |
| Total liabilities | $m | [22.2](/filings/0001213900-24-113150.md) | not reported | not reported | not reported | [38.2](/filings/0001213900-25-125331.md) | [49.2](/filings/0001213900-25-014320.md) | [55.8](/filings/0001213900-25-043359.md) | [59.3](/filings/0001213900-25-074992.md) | [56.1](/filings/0001213900-26-090184.md) | [51.6](/filings/0001213900-26-015877.md) | [65.4](/filings/0001213900-26-057841.md) | [71.7](/filings/0001213900-26-090184.md) |
| Shareholders' equity | $m | [25.5](/filings/0001213900-25-125331.md) | [22.7](/filings/0001213900-25-074992.md) | [19.8](/filings/0001213900-25-074992.md) | [17.0](/filings/0001213900-25-074992.md) | [46.1](/filings/0001213900-26-090184.md) | [41.3](/filings/0001213900-26-090184.md) | [35.6](/filings/0001213900-26-090184.md) | [32.4](/filings/0001213900-26-090184.md) | [44.9](/filings/0001213900-26-090184.md) | [58.4](/filings/0001213900-26-090184.md) | [35.3](/filings/0001213900-26-090184.md) | [40.4](/filings/0001213900-26-090184.md) |

- Cash and equivalents: us-gaap:Cash, us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(169)](/filings/0001493152-24-020783.md) | [(100) d](/filings/0001493152-24-030991.md) | [(113) d](/filings/0001493152-23-042170.md) | [(219) d](/filings/0001493152-24-014850.md) | [(192)](/filings/0001493152-24-020783.md) | [(366) d](/filings/0001493152-24-030991.md) | [(7,355)](/filings/0001213900-26-015877.md) | [(3,832) d](/filings/0001213900-26-057841.md) | [(2,711) d](/filings/0001213900-26-090184.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [6.6](/filings/0001493152-24-020783.md) | [6.6](/filings/0001493152-24-030991.md) | [6.6](/filings/0001493152-23-042170.md) | [67.5](/filings/0001213900-25-014320.md) | [67.5](/filings/0001213900-25-043359.md) | [67.5](/filings/0001213900-25-074992.md) | [71.6](/filings/0001213900-26-015877.md) | [71.6](/filings/0001213900-26-057841.md) | [71.6](/filings/0001213900-26-090184.md) | [87.5](/filings/0001213900-26-015877.md) | [100](/filings/0001213900-26-057841.md) | [108](/filings/0001213900-26-090184.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 92,981,204 at 2026-08-13, from the cover of the [10-Q filed 2026-08-14](/filings/0001213900-26-090184.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.